United StatesInteragency Patent Coordination and Improvement Act of 2025
What it does
This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.
More detail
The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2025
- Apr 10Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.Latest
- Apr 10Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.
- Apr 3Committee on the Judiciary. Ordered to be reported with amendments favorably.
- Mar 24Introduced in Senate
- Mar 24Read twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)Introduced